Definium Therapeutics, Inc.

Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for psychiatric and neurological disorders. Headquartered in New York City, the company applies scientific rigor to psychedelic-based medicine to address underlying disease mechanisms rather than temporary symptom relief. Definium’s lead program centers on DT120, an orally disintegrating tablet formulation of lysergide (LSD) being evaluated in late-stage clinical trials for major depressive disorder and generalized anxiety disorder, where it has received FDA Breakthrough Therapy Designation for GAD. The company is also advancing DT402, the R-enantiomer of MDMA, targeting core symptoms of autism spectrum disorder, particularly social communication challenges. Operating within the pharmaceuticals and biotechnology sectors, Definium Therapeutics occupies a specialized position in the emerging field of evidence-based psychedelic therapeutics, aiming to provide accessible, scalable treatment options across high-burden mental health and brain health indications.